Arrigali Elizabeth M, Serban Monica A
Pharmaceutical Sciences and Drug Design Program, Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT, United States.
Montana Biotechnology Center, University of Montana, Missoula, MT, United States.
Front Pharmacol. 2022 Jun 9;13:907516. doi: 10.3389/fphar.2022.907516. eCollection 2022.
Hearing loss affects roughly 466 million people worldwide. While the causes of hearing loss are diverse, mechanistically, inflammation and oxidative stress have been identified as major players in hearing loss regardless of pathogenesis. Treatment options remain extremely limited and there is currently no FDA approved drug therapy. Studies indicate that antioxidants such as d-Methionine have shown some protective effects; however, these studies involved systemic or invasive localized delivery methods and highlighted the need for the development of minimally invasive localized therapeutic approaches. Described herein is the development of an antioxidant-conjugated system that shows prophylactic potential against oxidative damage and appears suitable for topical delivery. Specifically, our covalent conjugate of hyaluronan with d-Methionine shows cytocompatibility and protection from oxidative stress in two mouse cochlear cell lines (HEI-OC1 and SV-k1). Mechanistically, the data indicate that the protective effects of the conjugate are due to the hyaluronan-mediated cellular internalization of the antioxidant. Most notably, the conjugate can efficiently permeate through an round window membrane model without the loss of the attached antioxidant, for subsequent delivery of the therapeutic cargo to the hearing sensory cells. Collectively these findings show that the novel conjugate could be a potential topical preventive agent against hearing loss.
听力损失影响着全球约4.66亿人。虽然听力损失的原因多种多样,但从机制上讲,无论发病机制如何,炎症和氧化应激已被确定为听力损失的主要因素。治疗选择仍然极其有限,目前尚无美国食品药品监督管理局(FDA)批准的药物疗法。研究表明,如d-蛋氨酸等抗氧化剂已显示出一些保护作用;然而,这些研究涉及全身或侵入性局部给药方法,并强调了开发微创局部治疗方法的必要性。本文描述了一种抗氧化剂共轭系统的开发,该系统显示出对氧化损伤的预防潜力,似乎适合局部给药。具体而言,我们的透明质酸与d-蛋氨酸的共价共轭物在两种小鼠耳蜗细胞系(HEI-OC1和SV-k1)中显示出细胞相容性并能保护细胞免受氧化应激。从机制上讲,数据表明共轭物的保护作用是由于透明质酸介导的抗氧化剂细胞内化。最值得注意的是,共轭物可以有效地透过圆窗膜模型,而不会损失附着的抗氧化剂,从而将治疗物质递送至听觉感觉细胞。这些发现共同表明,这种新型共轭物可能是一种潜在的预防听力损失的局部用药。